FDA Needs New Standards for Studying Alzheimer's Drugs
In the end, it may turn out that attacking today's biomarkers may not prevent Alzheimer's. The answer, though, won't be known unless the FDA revises its rules, a gamble we may want to take given the alternative.
fda need new standards study alzheimer drug end turn attack today biomarker prevent alzheimer answer will know fda revise rule gamble want give alternative